Astellas Buys Xyphos
Astellas buys Xyphos . Astellas Pharmaceuticals buys Xyphos Biosciences for up to $655 million including potential development milestones. Xyphos is focused on the creation and development of immuno-oncology therapeutics aimed to use the power of our immune system to cure cancer. Xyphos ' ACCEL (Advanced Cellular Control through Engineered Ligands ) tech platform allows new ways to activate and control immune cells to find and destroy precisely targeted cells in our body. The platform enables our immune cells to be relayed by bispecific antibodies or to be re-programmed to express a flexible Chimeric Antigen Receptor (CAR). This tech enables the exclusive or preferred class delivery of single or multiple steering and modulating agents, including bispecific antibodies, cytokines, and kill functions. Resulting convertibleCAR-cells can be guided to tumor cells and tumor destruction can be controlled from outside the CAR-cell. Kenji...